[Effect of Kuanxiong aerosol on coronary heart disease angina patients: a multicenter randomized controlled clinical

Related Experiment Video

Updated: Apr 30, 2026

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model
07:35

Aggravation of Myocardial Ischemia upon Particulate Matter Exposure in Atherosclerosis Animal Model

Published on: December 10, 2021

1.8K

Li-Zhi Li, Guo-Ju Dong, Chang-Jiang Ge

    Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine
    |May 13, 2014
    PubMed

    Insights

    Kuanxiong Aerosol (KA) effectively relieved anginal attacks and improved ECG changes in coronary heart disease (CHD) patients. KA demonstrated a significantly lower adverse reaction rate compared to Nitroglycerin Tablet (NT).

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Trials

    Context:

    • Coronary heart disease (CHD) poses a significant global health burden, with angina pectoris being a primary symptom.
    • Current treatments for angina, such as Nitroglycerin Tablet (NT), are effective but can be associated with adverse reactions.
    • Novel therapeutic strategies are needed to improve angina relief and patient safety in CHD management.

    Purpose:

    • To evaluate the efficacy of Kuanxiong Aerosol (KA) in relieving anginal attacks in patients diagnosed with coronary heart disease (CHD).
    • To assess the safety profile of Kuanxiong Aerosol (KA) by comparing its adverse reaction rate with that of Nitroglycerin Tablet (NT).
    • To determine the impact of Kuanxiong Aerosol (KA) on electrocardiogram (ECG) changes indicative of myocardial ischemia.

    Summary:

    • A randomized controlled trial involving 780 CHD patients compared Kuanxiong Aerosol (KA) with Nitroglycerin Tablet (NT) for angina relief.
    • KA showed comparable efficacy to NT in relieving anginal attacks within 3 and 5 minutes, and in improving ST-T changes on ECG.
    • The treatment group using KA exhibited a significantly lower incidence of adverse reactions (9.31%) compared to the NT group (22.46%).

    Impact:

    • Kuanxiong Aerosol (KA) presents a viable alternative for angina management in CHD patients, offering comparable efficacy to NT with improved tolerability.
    • The reduced adverse reaction profile of KA could lead to better patient compliance and quality of life.
    • These findings support the integration of Kuanxiong Aerosol (KA) into clinical practice for the treatment of angina pectoris in coronary heart disease.
    Abstract

    More Related Videos

    Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders06:39

    Intracoronary Acetylcholine Provocation Testing for Assessment of Coronary Vasomotor Disorders

    Published on: August 18, 2016

    16.3K
    Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders05:58

    Testing Acetylcholine Followed by Adenosine for Invasive Diagnosis of Coronary Vasomotor Disorders

    Published on: February 3, 2021

    4.0K

    Related Concept Videos

    Antianginal Drugs: Nitrates and β-Blockers01:16

    Antianginal Drugs: Nitrates and β-Blockers

    In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
    Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
    1.9K
    Coronary Artery Disease III: Clinical Manifestations01:30

    Coronary Artery Disease III: Clinical Manifestations

    Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
    620
    Angina I: Introduction01:30

    Angina I: Introduction

    Definition and Symptoms: Angina (angina pectoris) is chest pain or discomfort caused by myocardial ischemia, which occurs when the heart muscle receives insufficient oxygen-rich blood. It typically manifests as pressing, squeezing, or crushing sensations in the chest and may radiate to the shoulders, arms, neck, jaw, or back.Primary Cause: In a healthy state, the coronary arteries can dilate (widen) to increase blood flow and meet the increased oxygen demand during physical activity or...
    808
    Angina IV: Management01:26

    Angina IV: Management

    IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
    491
    Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

    Antianginal Drugs: Calcium Channel Blockers and Ranolazine

    Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
    CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
    1.9K
    Coronary Artery Disease V: Interprofessional Care01:27

    Coronary Artery Disease V: Interprofessional Care

    Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
    444